Cargando…

P1107: CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

Detalles Bibliográficos
Autores principales:	Dharnidharka, V., Thirumalai, D., Jaeger, U., Zhao, W., Dierickx, D., Xun, P., Minga, P., Sawas, A., Sadetsky, N., Chauvet, P., Sundaram, E., Barlev, A., Zimmerman, H., Trappe, R. U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429676/ http://dx.doi.org/10.1097/01.HS9.0000847296.83232.25

Ejemplares similares

P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
por: Sanz-Caballer, J., et al.
Publicado: (2022)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES
por: Choquet, S., et al.
Publicado: (2022)

P1388: EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY (TABELECLEUCEL) UNDER AN EXPANDED ACCESS PROGRAM IN EUROPE
por: Choquet, Sylvain, et al.
Publicado: (2023)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD
por: Habib, Mohammed, et al.
Publicado: (2017)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)
por: Kris Michael, Mahadeo, et al.
Publicado: (2023)

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient
por: Afshar, Kamyar, et al.
Publicado: (2011)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

PReS13-SPK-1107: Development of an academic pediatric rheumatology program
por: Laxer, R
Publicado: (2013)

1107. The MAAGE Study: Health Care Utilization for the Treatment of Medically Attended Acute Gastroenteritis
por: Mattison, Claire P, et al.
Publicado: (2018)

1107. Vancomycin AUC Dosing: Is One Concentration in the Hand Worth Two in the Bush?
por: Spivey, Justin, et al.
Publicado: (2021)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009
por: Andersson, Niklas, et al.
Publicado: (2018)

1107. Third Generation Cephalosporins Monotherapy Experience in Pediatric Patients with High-Risk Febrile Neutropenia
por: Gutierrez, Valentina, et al.
Publicado: (2020)

Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment
por: Li, Xiaofan, et al.
Publicado: (2015)

Understanding celiac disease monitoring patterns and outcomes after diagnosis: A multinational, retrospective chart review study
por: Lundin, Knut EA, et al.
Publicado: (2021)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT
por: Kissane, E., et al.
Publicado: (2022)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient
por: Ventura-Aguiar, P., et al.
Publicado: (2019)

SG-APSIC1107: Effectiveness of interventions increasing surgical hand hygiene compliance at Hung Vuong Hospital
por: Dinh, Anh, et al.
Publicado: (2023)

Training in the evaluation of pesticides (plant protection products and active substances) according to Regulation (EC) No 1107/2009
por: Cilia, Nicole, et al.
Publicado: (2023)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

1107. Impact of Routine Education and Data Feedback on the Durability of an Antimicrobial Stewardship Intervention for Outpatient Urinary Tract Infections
por: Funaro, Jason, et al.
Publicado: (2019)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016)

Good function after shoulder arthroplasty: 1,107 patients with 4 different diagnoses from the Norwegian Arthroplasty Register
por: Fevang, Bjørg-Tilde S, et al.
Publicado: (2012)

A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults
por: Lee, Jacob, et al.
Publicado: (2019)

Single-Disulfide Conopeptide Czon1107, an Allosteric Antagonist of the Human α3β4 Nicotinic Acetylcholine Receptor
por: Ma, Yuan, et al.
Publicado: (2022)

Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population
por: Ali, Hatem, et al.
Publicado: (2020)

Sterile necrotizing and non-necrotizing granulomas in a heart transplant patient with history of PTLD: A unique finding
por: Piening, Nicholas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g1v70ilncplv4oo05ubf6itoh0